NEW YORK, Sept 21 – The US National Cancer Institute (NCI) has purchased Nanogen’s (Nasdaq: NGEN) NanoChip system for use in cancer research and diagnosis, Nanogen said Thursday.

“The NanoChip system may accelerate this process, allowing us to potentially use this same tool in both the research process and in the patient care process,” Stephen Chanock of the NCI’s Pediatric Oncology Branch at the Advanced Technology Center said in a statement.

Terms of the deal were not disclosed. Representatives of NCI and Nanogen could not immediately be reached for comment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.